Cingulate Inc. (CING)
NASDAQ: CINGHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CING stock chart
Technical analysisKey statistics
All statistics- Market cap
- $67.48M
- EPS (TTM)
- -$2.67
- Dividend yield
- None
- 52-week range
- 3.16 – 11.89
- Day range
- 4.40 – 5.24
- Volume / Avg
- 973.91K / 178.82K
- Beta
- —
- Shares outstanding
- 14.96M
52-week range
CING stock today
Shares of Cingulate (CING) finished lower on Nov 20 at $4.51, a drop of 14.26% or $0.75 per share, versus the S&P 500's 3.70% decline. Volume was 5.4x the average at 973.91K shares, a sign of unusually heavy trading. Shares are 62.1% below their 52-week high of $11.89, set on Mar 17, 2026 and 42.7% above the 52-week low of $3.16, near the bottom of the past year's range.
CING is up 3.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 27.8%. Cingulate has posted a net loss over the last twelve months (EPS of -$2.67), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cingulate
Company profileCingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Shane J. Schaffer Pharm.D.
- Headquarters
- Kansas City, KS
- Employees
- 14
- IPO year
- 2021
- Website
- cingulate.com
Financial highlights
Full financialsCingulate reported a net loss of $22.4 million, compared with a loss of $16.6 million a year earlier. Diluted earnings per share came in at -$4.44.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-22.45M | $-16.56M | $-23.53M | $-17.68M | $-20.71M |
| EPS (diluted) | $-4.44 | $-10.86 | $-311.99 | $-29.35 | $-2.79 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$21.20+370.07%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.53 vs $-0.48
- Surprise
- -10.42%
CING news
All CING news- Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology PlatformGlobeNewswire
- Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA ResubmissionGlobeNewswire
- Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane KingGlobeNewswire
Cingulate peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MNOVMedicinova Inc | 1.31 | +3.15% | $67.11M | vs CING |
| MAIAMAIA Biotechnology Inc. | 1.11 | -2.63% | $68.54M | vs CING |
| PLYXPolaryx Therapeutics Inc. | 1.33 | -11.92% | $66.30M | vs CING |
| PMVPPMV Pharmaceuticals Inc. | 0.876 | -33.13% | $66.17M | vs CING |
| COYACoya Therapeutics Inc. | 2.95 | -1.01% | $69.20M | vs CING |
| GOSSGossamer Bio Inc. | 10.72 | -4.54% | $65.57M | vs CING |
| ZYBTZhengye Biotechnology Holding Limited Class A | 1.48 | -2.63% | $70.14M | vs CING |
| FBIOFortress Biotech Inc. | 1.90 | +7.34% | $64.11M | vs CING |
Indexes, lists and sector
Cingulate stock FAQ
What is Cingulate's stock price today?
CING last traded at $4.51 as of Nov 20, 4:00 PM EST, down 14.26% on the day. Prices are delayed at least 15 minutes.
Does Cingulate pay a dividend?
No. Cingulate does not currently pay a regular cash dividend.
Who is Cingulate's CEO?
Dr. Shane J. Schaffer Pharm.D. is the chief executive officer of Cingulate Inc., which has about 14 employees.
Has CING ever split its stock?
Yes. The most recent CING stock split was a 1-for-12 split on Aug 9, 2024, one of 2 splits on record.
What is the CING 52-week high?
The 52-week high for CING is $11.89 and the 52-week low is $3.16. The stock is currently 62.1% below its high.